Mubadala Investment, a sovereign investor, and The Column Group, a science-driven venture capital firm, led a $236m Series D funding round in Kallyope, an operator of a biotechnology company, with participation from Alexandria Venture Investments, Bill Gates, Casdin Capital, Euclidean Capital, Illumina Ventures, Lux Capital, Polaris Partners, Two Sigma Ventures, StepStone Group, DNS Capital, Hartford Healthcare Endowment, Parkwood and Tao Capital. “Since our inception six years ago, Kallyope has pioneered research on the gut-brain axis and developed a transformational drug discovery platform with speed and ingenuity. We are now positioned at the forefront of this space. We are pleased with the support of an outstanding group of investors who represent a strong vote of confidence in our science and our team," Jay Galeota, Kallyope President and CEO.